☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
AbbVIe
AbbVie Partners with Gilgamesh Pharmaceuticals to Develop Next-Generation Therapies for Psychiatric Disorders
May 14, 2024
AbbVie Reports Data from the P-III Trial of Atogepant as a Preventive Treatment of Migraine
April 15, 2024
AbbVie Reports the Acquisition of Landos Biopharma for ~$212.5M
March 26, 2024
Top 20 Women Health Focusing Companies of 2024 Based on Market Cap
March 14, 2024
AbbVie and OSE Immunotherapeutics Join Forces for the Development of OSE-230 to Treat Chronic Inflammation
February 28, 2024
AbbVie and Tentarix Biotherapeutics Join Forces for the Development of Biologics for Oncology and Immunology
February 24, 2024
Load more...
Back to Home